Generic Drug Development Efficiency: The Complete Playbook for IP Teams, Portfolio Managers, and R&D Leads
Generic drugs account for 91% of all U.S. prescriptions dispensed while consuming less than 20% of total drug spend. That […]
Pharmaceutical Licensing Agreements: The Complete IP Valuation, Deal Architecture, and Strategy Guide for Pharma/Biotech Leaders
Pharmaceutical Licensing Agreements: The Complete IP Valuation, Deal Architecture, and Strategy Guide for Pharma/Biotech Leaders Pharmaceutical licensing is, at its
AI-developed Drugs Bring IP and Regulatory Risks: Navigating the New Frontier of Pharmaceutical Innovation
1. Scale and Economics: What AI Actually Costs and What It Might Deliver The pharmaceutical industry’s standard development timeline averages
Real World Blockchain Uses in the Pharmaceutical Industry
The expiration of primary patents on high-value therapeutics, frequently termed the patent cliff, creates a predictable revenue vacuum for innovators.
Real World Blockchain Uses in the Pharmaceutical Industry Read Post »
How Premarin Maintained Market Dominance Without Patent Protection
The Architecture of Resilience: A Comprehensive Analysis of Premarin’s Sustained Market Dominance Without Patent Protection The pharmaceutical industry operates on
How Premarin Maintained Market Dominance Without Patent Protection Read Post »
Drug Patent Opposition Proceedings: The Complete Playbook for IP Teams, Generic Challengers, and Portfolio Investors
Patent opposition is where pharma IP stops being administrative paperwork and starts functioning as competitive strategy. A single successful opposition
Generic Drug Clinical Studies: The Complete ANDA Playbook for Bioequivalence Success
There is a persistent myth in the pharmaceutical industry that generic drug development is a reduced-complexity, paint-by-numbers exercise. You take
Generic Drug Clinical Studies: The Complete ANDA Playbook for Bioequivalence Success Read Post »
How Innovator Pharma Companies Outmaneuver Generic Rivals: The Complete Tactical Playbook for Lifecycle Management, Patent Strategy, and Post-Exclusivity Market Defense
1. Why Generic Defense Requires a Ten-Year Lead Time The time to begin planning for generic competition is the day
Drug Patent Portfolio Management: The Complete Playbook for Pharma IP Teams, Portfolio Managers, and R&D Leads
The pharmaceutical company that treats its patent portfolio as a legal filing system is the one that gets ambushed at
